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Abstract
Objectives Conventional X-ray attenuation-based contrast is
inherently low for the soft-tissue components of the female
breast. To overcome this limitation, we investigate the diag-
nostic merits arising from dark-field mammography by means
of certain tumour structures enclosed within freshly dissected
mastectomy samples.
Methods We performed grating-based absorption, absolute
phase and dark-field mammography of three freshly dissected
mastectomy samples containing bi- and multifocal carcinoma
using a compact, laboratory Talbot-Lau interferometer. Preop-
erative in vivo imaging (digital mammography, ultrasound,
MRI), postoperative histopathological analysis and ex vivo
digital mammograms of all samples were acquired for the
diagnostic verification of our results.
Results In the diagnosis of multifocal tumour growth, dark-
field mammography seems superior to standard breast imag-
ing modalities, providing a better resolution of small, calcified
tumour nodules, demarcation of tumour boundaries with
desmoplastic stromal response and spiculated soft-tissue
strands extending from an invasive ductal breast cancer.
Conclusions On the basis of selected cases, we demonstrate
that dark-field mammography is capable of outperforming
conventional mammographic imaging of tumour features in
both calcified and non-calcified tumours. Presuming dose op-
timization, our results encourage further studies on larger pa-
tient cohorts to identify those patients that will benefit the
most from this promising additional imaging modality.
Key Points
• X-ray dark-field mammography provides significantly
improved visualization of tumour features
• X-ray dark-field mammography is capable of outperforming
conventional mammographic imaging
• X-ray dark-field mammography provides imaging sensitivity
towards highly dispersed calcium grains
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Introduction
With the implementation of nationwide screening programs in
many countries, breast cancer mortality has steadily declined
over the past decades [1]. Technical developments in conven-
tional breast imaging have led to a significantly improved
detection of early breast cancer and pre-invasive breast
lesions. However, breast cancer remains the leading cause
of cancer death in women worldwide [2] and underlying
imaging techniques continue to havemajor limitations in daily
clinical routine: while being the standard screening technique,
the diagnostic sensitivity of conventional mammography
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remains fairly low, especially in women with dense breast
tissue [3] and women at high familial risk of breast cancer
[4, 5]. Supplemental screening ultrasound is operator-
dependent and time-consuming [6]. MRI offers the highest
diagnostic sensitivity for the detection of small cancers and
has the advantage of avoiding ionizing radiation, but has low
spatial resolution, is cost-intensive and requires the use of
intravenous contrast agents [7].
Conventional X-ray mammography is based on
attenuation-based contrast which is inherently low within
breast soft tissue [8]. In the case of X-ray energies used in
clinical mammography, phase-contrast and dark-field imaging
are capable of overcoming these limitations as image forma-
tion in these modalities relies on the intrinsically enhanced
electron density contrast and small-angle scattering capability
of the tissue, respectively [8–10]. Besides, dark-field imaging
benefits from sub-resolution sensitivity [11], which enables
the detection of microstructures within the breast that are
smaller than the pixel pitch of the detector [12, 13]. With
the recent introduction of a grating-based imaging approach
utilizing a Talbot-Lau interferometer, retrieval of phase-
contrast and dark-field signal is no longer restricted to
highly brilliant X-ray sources, but is now compatible with
clinical X-ray sources [14, 15]. First studies investigating
mastectomy samples with laboratory-based phase-contrast
mammography showed promising results with respect to
diagnostic potential by means of improved tumour visuali-
zation [16], image quality [17] and enhanced detection of
ultra-small microcalcifications [12, 13].
In this work, we present the first specific case study of
dark-field and absolute phase-contrast mammography con-
ducted with two scanning directions using freshly dissected
mastectomy specimens containing bi- and multifocal breast
cancer (Table 1). We demonstrate that dark-field imaging
alone results in improved visualization of tumour-infiltrated
soft-tissue strands, multifocality, tumour boundaries and small
calcified tumour clusters yet undifferentiated with conventional
imaging techniques. Our results demonstrate the diagnostic
merit of phase-contrast mammography for these specific
tumour characteristics and encourage further efforts towards
a rapid implementation into clinical routine.
Materials and methods
Study design and sample acquisition
The study was conducted in accordance with the Declaration
of Helsinki and was approved by the local ethics committee
(Ethikkommission of the Ludwig-Maximilian-University,
Munich, project number 240–10, date of permission 26/08/
2010, amendment 30/05/2012). The three selected patients
suffering from multifocal breast cancer were chosen from a
collective of a prospective study on ex vivo phase-contrast
mammography. From September 2012 to March 2013, all
patients undergoing mastectomy were asked to take part in
the study. All participants gave written informed consent
before inclusion after adequate explanation of the study
protocol. Indication for breast surgery followed recommen-
dation of the interdisciplinary tumour conference. Inclusion
criteria were a histologically proven breast cancer in preop-
erative core biopsy with a recommendation for mastectomy
according to gynaecological guidelines or the patient’s wish
for mastectomy as well as completed preoperative conven-
tional breast diagnostics (mammography, ultrasound with or
without MRI).
Preoperative diagnostics
Preoperative diagnostics included clinical breast examina-
tion, clinical standard two-view digital mammography in
craniocaudal (CC) and mediolateral-oblique (MLO) projec-
tions (Hologic Selenia Dimensions, Bedford, USA) using
a standard breast compression paddle and high resolution
Table 1 Tumour characteristics of patients 1–3: histological diagnosis
and tumour type; classification of mammographic breast density
according to the American College of Radiology (ACR); preoperative
imaging according to the Breast Imaging Reporting and Data System
(BIRADS); dimensions and weight of the breast samples; maximum
tumour size according to histopathology; TNM classification





1 Multifocal invasive carcinoma of no
special type (NST, formerly invasive
ductal), G1
II IV 16.5×10.5×9 cm3
501 g
40 mm pT2(m) pN1a (1/16) Mx
2 Trifocal invasive carcinoma of no special
type (NST, formerly invasive ductal)
and invasive lobular carcinoma, G1–2
II IV 25×18×4.5 cm3
1009 g
15 mm pT1c (trifocal) pN2a (7/16) Mx
3 Bifocal carcinoma of no special type
(NST, formerly invasive ductal) G2
II V 26×13.5×2.5 cm3
570 g
25 mm pT2(m) pN0 Mx
Note that the smallest sample diameter is measured in antero-posterior direction and does not correspond to the maximum craniocaudal diameter used for
the experimental mammography
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B-mode ultrasound (standard linear transducer 13.5 MHz,
Siemens Acuson Antares, Siemens Healthcare, Germany).
In one patient additional MRI was performed by using a
dedicated sensitivity-encoding-enabled bilateral breast coil with
a 3.0-Tesla system (Magnetom Verio, Siemens Healthcare,
Germany).
Ex vivo clinical mammography
The mastectomy samples were intraoperatively marked with
surgical sutures for 3D orientation. The samples were fixed in
craniocaudal position within a metal-framed sample holder to
afford adequate breast compression. In order to ensure com-
parability, both a digital ex vivo mammography at a clinical
mammography unit (Hologic Selenia Dimensions, Bedford,
USA) with a pixel size of 70×70 μm2 and an experimental
phase-contrast mammography with an effective pixel size of
85×85 μm2 were conducted without changing the sample
position within the sample holder.
Phase-contrast mammography setup
A three-grating Talbot-Lau interferometer consisting of a con-
ventional X-ray tube, a source grating G0, a phase grating G1
and an analyser grating G2 (Microworks GmbH, Germany)
was used for the experimental measurements. The source
grating provides a spatially coherent X-ray beam, the
phase grating generates an interference pattern downstream
of the beam and the analyser grating detects changes of
the latter, when a specimen is introduced into the beam,
by which retrieval of phase- and dark-field contrast is
practicable. A compact layout (distance G0–G1 1 m and
G1–G2 0.5 m) in the third Talbot order was chosen using
a Varian Paxscan 2520D flat panel with Gadox screen and
127×127 μm2 pixel size (effective pixel size of 85×85 μm2).
The sample was positioned 2.7 cm upstream of G1. The
Nonius FR 591 rotating anodeX-ray tube (molybdenum target)
was set to 40 kVp/70 mA (detailed description in [18]).
Data acquisition
A field of view of 12.8×12.8 cm2 was achieved by stitching
together 4×4 single projections.
Each scan was conducted with nine phase steps and an
exposure time of 9 s each. Case study 1 and 3 were conducted
with a bidirectional scanning approach, for the purpose
of providing full detection sensitivity and absolute phase
images as demonstrated in [18]. The phase image shown
in case study 2 was obtained by a regularized 1D inte-
gration [19]. In order to increase image sharpness, phase
images were high-frequency boosted.
Dose
The average glandular radiation dose of the in vivo mammog-
raphy automatically registered by the mammography unit was
0.40 and 0.41 mGy for sample 1, 1.21 and 1.27 mGy for
sample 2 and 1.35 and 1.26 mGy for sample 3 (mediolateral
oblique projection and craniocaudal projection, respectively).
The average glandular radiation dose of the ex vivo clinical
mammography was 0.56 mGy for sample 1, 1.22 mGy for
sample 2 and 1.18 mGy for sample 3. The radiation dose of
the experimental mammography was approximated by deter-
mining the incident air kerma (2.1 mGy/s) with a Dosimax
plus/RQX detector system. The mean glandular dose was cal-
culated by weighting this value with a Monte Carlo-based
conversion factor of 0.389–0.422, determined by the half-
value layer (Al) of 0.8 mm and breast thicknesses ranging
from 4.5 to 5.0 cm [20, 21].
Histological workup
Image data acquisition was followed by standard histological
workup according to histopathological diagnostic guidelines.
The mastectomy samples were fixated in a 4 % neutral-
buffered formaldehyde solution immediately after image
acquisition. The formaldehyde-fixated samples were cut
into 5-mm slices. Representative tissue sections were
dehydrated in an ascending alcohol series before embed-
ding in hot paraffin wax. The paraffin blocks were cut
into 5-μm sections using a standard microtome and sec-
tions were stained with haematoxylin and eosin using
standard protocols.
Correlation phase-contrast mammography, ex vivo
mammography, in vivo imaging and histology
Phase-contrast and dark-field mammography of each sample
were compared with preoperative in vivo standard imaging
in consensus by three radiologists experienced in breast
diagnostics who were blinded for the histopathological di-
agnosis. Afterwards, the findings were correlated with cor-
responding histological sections by a pathologist specialized
in breast diagnostics.
Results
Dark-field mammography reveals radiographically
undetectable tumour nodules
Patient 1 presented with a histologically proven recurrent
breast carcinoma of the contralateral left breast after breast-
conserving therapy (data not shown). Additionally, two nod-
ular indurations of the right breast in the upper lateral quadrant
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Fig. 1 Dark-field mammography
reveals radiographically
undetectable tumour nodules.
Clinical ex vivo mammography
in craniocaudal (cc) projection at
31 kVp, 45 mAs and 0.56 mGy





(PC-Mx, c) and dark-field
mammography (DF-Mx, d) of
patient 1 at 40 kVp, 70 mA and
66 mGy mean glandular dose
(per scan direction);
representative section from the
in vivo MRI (e) including
contrast-enhanced T1 weighted
gradient-echo sequence after
manual injection of 0.2 ml/kg
meglumine gadopentetate
(Magnograf ® 0.5 mmol/ml)
(e, left) and the corresponding
first subtraction image after 2 min
(e, right) in an axial view using a
dedicated sensitivity-encoding-
enabled bilateral breast coil with a
3.0-Tesla system (voxel size
0.7×0.7×2.0 mm), field of view
360 mm; base resolution 512; flip
angle 15°; repetition time 6.5 ms;
echo time 2.47ms. Ultrasound (f);
vertical line plots quantifying
superior depiction of tumor (TU)
1, 2 and 3 in DF-Mx (g, bottom)
in comparison with abs-Mx
(g, top) as indicated by arrows;
in vivo mammography of patient
1 in cc projection at 29 kVp, 11
mAs and 0.41 mGy average
glandular dose (aluminium filter)
(h); exemplary histological image
(haematoxylin–eosin staining) of
one calcified tumour nodule
(i and j), arrows indicating
microcalcifications. The
rectangles in a–d and h indicate
TU 1–3. The crossed arrows in
b–d indicate bidirectional
measurements
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were clinically suspicious. Conventional in vivo mammogra-
phy (IV-Mx) of the right breast revealed two corresponding
adjacent lesions (Fig. 1h, white box) measuring 5 and 2 mm in
the right upper lateral quadrant. Ultrasound revealed altogeth-
er seven suspicious lesions of 3 to 8 mm diameter in the upper
lateral right quadrant three of which are shown in Fig. 1f.
Dynamic MRI showed two suspicious enhancing lesions in
the upper lateral quadrant of the right breast corresponding to
the in vivo mammography (Fig. 1e). Histopathology of the
whole breast revealed a multifocal carcinoma of no special
type (NST, formerly invasive ductal carcinoma) grade 1 with
the single tumor nodules measuring up to 6 mm and a maxi-
mum total diameter of 4 cm within an extensively growing
ductal carcinoma in situ (6 cm).
Figure 1a–d shows ex vivo clinical mammography (EV-
Mx), experimental absorption-contrast mammography (abs-
Mx), phase-contrast mammography (PC-Mx) and dark-field
mammography (DF-Mx) of the breast specimen 1 in
craniocaudal orientation, which support the mammographic
findings of two separated tumour nodules (TU1 and TU3),
although being partially superimposed by surrounding breast
parenchyma and resection margins. Surprisingly, in the DF-
Mx (see Fig. 4a for the respective low-dose image) five addi-
tional smaller spots of high scattering contrast, composing a
thi rd nodule (TU2) , were detec ted between the
mammographically verified nodules TU1 and TU3. The spa-
tial arrangement of the additional strongly scattering nodules
within the DF image is consistent with the corresponding ul-
trasound section, showing a hypoechogenic Bbridge^
connecting the very lateral TU1 and TU2 as well as the third
nodule TU3. The detection of an additional, intermediate nod-
ule may explain why the first nodule TU1 is presented distinc-
tively enlarged within the MRI in comparison to TU3: the low
spatial resolution of MRI in combination with a continuous
perfusion of contrast agent within TU1 and TU2 seems to
depict the latter falsely as one persuasive tumour mass. Histo-
pathological workup (Fig. 1i, j) proved the nodules with high
DF contrast to be small calcified tumour nodules of 6 mm
maximum diameter. Since the overal l volume of
microcalcified tissue is small, linear extinction coefficient
(EV-Mx, abs-Mx) and electron density (PC-Mx) of the tumor-
ous tissue are hardly altered by the presence of calcium, which
leads to a visual blurring of the tumour within the surrounding
breast parenchyma. However, imaging sensitivity in DF-Mx is
enhanced towards ultra-small calcifications in the size range
of some microns, accounting for the strong scattering signal
provided by microcalcified structures within the tumour nod-
ules. The surrounding breast parenchyma does not contribute
to the scattering signal, which enables a clear differentiation of
the small calcified tumour nodules from the surrounding
breast tissue. Vertical line plots in abs-Mx (Fig. 1g, top) and
DF-Mx (Fig. 1g, bottom) visualize the superior depiction of
all tumour nodules by means of DF-Mx. Contrast-to-noise
ratios (difference between signal intensities of tumour and
respective surrounding tissue, divided by the standard devia-
tion of the pure image noise) of 14.28 (TU1), 4.82 (TU2) and
7.76 (TU3) in the DF-Mx by far exceed those in the abs-Mx of
3.58 (TU1), 1.71 (TU2) and 4.14 (TU3). In the presented case,
DF-Mxwas the only radiographic imaging modality depicting
and detecting additional tumour nodules correctly, yet unde-
tectable or spatially unresolved within conventional mam-
mography and MRI.
Dark-field mammography reveals pervasion of the breast
with partially tumorous soft-tissue strands
Patient 2 presented with a palpable mass in the upper lateral
quadrant of the left breast. IV-Mx (Fig. 2e) shows a mass
lesion of 7 mm diameter in the upper lateral quadrant of the
left breast associated with a suspicious architectural distortion.
Ultrasound showed a corresponding suspicious architectural
distortion measuring 14×12×8 mm3 with typical posterior
acoustic shadowing. Histopathology of the whole breast re-
vealed a trifocal carcinoma with the single tumours lying di-
rectly adjacent to each other including an intermediate grade
(G2) carcinoma NSTand an intermediate to low grade (G2–3)
invasive lobular carcinoma.
Figure 2a–d shows EV-Mx, abs-Mx, PC-Mx and DF-Mx
of sample 2. Histological images in haematoxylin-eosin stain-
ing show parts of the tumour-infiltrated tissue strands origi-
nating from the main tumour (Fig. 2f, g). Spiculated soft-
tissue strands originating from the tumour and perfusing the
surrounding tissue within a distance of approximately 2 cm
were detected in all image modalities. However, in the DF-
Mx, the extension of the strands was distinctively vaster than
suggested by the other image modalities, even reaching up to
the posterior resection margin (inlays in Fig. 2d). Histology
revealed that the tissue strands consist of vessels and are par-
tially infiltrated by tumour cells. The poor differentiability of
the spiculated strands in IV-Mx, EV-Mx, abs-Mx and PC-Mx
within the surrounding tissue can mainly be attributed to the
small diameter (1–1.5 mm) of the strands in comparison to the
underlying breast tissue (5 cm) in the beam direction as well as
the fact that the differences in electron density between the
tissue strands and the surrounding fatty breast tissue are rela-
tively low. Hence the effective change in linear extinction
coefficient (EV-Mx, abs-Mx) and electron density (PC-Mx)
induced by the tissue strands with respect to the embedding
tissue is minor, resulting in a poor contrast which is insuf-
ficient for proper delineation of the tissue strands from the
surrounding tissue (CNR=0.86). However, the scattering
properties within the strands strongly differ from the sur-
rounding tissue. By means of DF-Mx, a clear differentiation
(CNR=3.98) from the surrounding tissue was achieved, be-
cause scatter caused by the vessels and cellular structures
within strands is not limited by their thickness. Although the
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micromorphology of the strands remains spatially unresolved,
sub-resolution sensitivity towards the inherent structures is
provided by the dark-field signal. Thus, the small-angle scat-
tering signal caused by vascular walls and structures with high
cellularity is detected by DF-Mx. Since inherent structures are
mostly aligned alongside the strands, scatter is directed unidi-
rectionally resulting in the adding up of signal. Besides, fatty
tissue is hardly scattering, resulting in a flat background signal
facilitating the depiction of the fine tumour strands from the
surrounding tissue, yet undetectable in conventional imaging.
Fig. 2 Dark-field mammography reveals pervasion of breast with
partially tumorous soft-tissue strands. Clinical ex vivo mammography
in craniocaudal (cc) projection at 29 kVp, 120 mAs and 1.22 mGy
average glandular dose (rhodium filter) (a), experimental absorption-
contrast mammography (b), phase-contrast mammography (c) and
dark-field mammography (d) at 40 kVp, 70 mA and 66 mGy mean
glandular dose (per scan direction); in vivo mammography in cc
projection at 29 kVp, 105 mAs and1.27 mGy average glandular dose
(rhodium filter) (e) of patient 2 in craniocaudal projection; blue
rectangles in a and e indicate the trifocal carcinoma; white rectangles in
a–e indicate partially infiltrated tissue strands emerging from the tumour;
exemplary histological image (haematoxylin–eosin staining) of partially
tumour-infiltrated tissue strands (f) and (g) indicated by arrows. The
arrows in b–d indicate one-directional measurements
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With the information obtained by DF-Mx available in the
preoperative mammogram of this patient, an additional
preoperative MRI would likely have been recommended
for clarifying the tumour extent with respect to pectoral
muscle infiltration.
Phase-contrast and dark-field mammography reveal
tumour margins
Patient 3 presented with a palpable mass in the upper lateral
quadrant of the left breast. Palpation revealed two suspicious
Fig. 3 Phase-contrast and dark-field mammography reveal tumour
margins. Clinical ex vivo mammography in craniocaudal (cc) projection
at 27 kVp, 120 mAs and 1.18 mGy average glandular dose (rhodium
filter) (a), experimental absorption-contrast mammography (b), phase-
contrast mammography (c) and dark-field mammography (d) at
40 kVp, 70 mA and 70 mGy mean glandular dose (per scan direction);
in vivo mammography in cc projection at 29 kVp, 125 mAs and
1.26 mGy average glandular dose (rhodium filter) (e) of patient 3 in
craniocaudal projection; white rectangle indicating tumour 1; ultrasound
of tumour 1 (f); histological image (haematoxylin–eosin staining) of
tumour 1 (g); the posterior margin of tumour 1 is indicated by black
arrows in c, d and g. The crossed arrows in b–d indicate bidirectional
measurements
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indurations: in the left upper lateral and in the left lower me-
dial quadrant. IV-Mx (Fig. 3e) revealed a suspicious mass
(tumour 1), measuring 14×9 mm2 in the left lower medial
quadrant which was mainly superimposed by breast parenchy-
ma. A second mass of 12×8 mm2 was found in the left upper
lateral quadrant (tumour 2). Sonographically (Fig. 3f shows
tumour 1), both tumours had typical malignant features such
as poor echogenicity, blurred margins and a hyperechogenic
rim. Histopathology revealed tumour 1 (Fig. 3g) as a 2.5×
1.2×1 cm3 moderately differentiated (G2) invasive carcinoma
NST, tumour 2 as a partially haemorrhagic, 2.5×2.3×2 cm3
moderately differentiated (G2) invasive carcinoma NST con-
taining a postbioptic haemorrhagic cavity.
Figure 3a–d shows EV-Mx, abs-Mx, PC- and DF-Mx of
sample 3. Note the air inclusions representing the tissue defect
at the biopsy site in tumour 2. Both tumour manifestations are
detectable within the resected breast in all modalities. In the
PC- and DF-Mx, an additional strong, linear contrast was
observed exclusively at the dorsal margin of tumour 1 (black
arrows in Fig. 3c, d), enabling a clear differentiation from the
adjacent breast tissue. Histopathological workup revealed a
desmoplastic stromal reaction and fibrous changes alongside
the edge of the tumour resulting in a sharp demarcation from
the surrounding tissue (black arrows in Fig. 3g). The distinct
separation of tissue is accompanied by a strong local variation
in refractive index across the tumour and adherent parenchy-
ma, which generates a high contrast within the phase signal.
Further X-rays are scattered at the tissue border alongside the
tumour margin as visible within the dark-field image signal.
Contrasting, absorption-based imaging (IV-Mx, EV-Mx and
abs-Mx) is hardly sensitive towards this specific tumour entity
and displays posterior and anterior tumourmargins in a similar
manner.
Discussion
In this ex vivo study on three selected mastectomy samples
containing bi- and multifocal carcinoma, we evaluated the
diagnostic value of grating-based phase-contrast and dark-
field mammography at a conventional, polychromatic X-ray
source. We showed that dark-field mammography provides
complementary information in comparison with conventional
imaging, by revealing tissue strands emerging from the tu-
mour, detecting microcalcified tumour nodules and depicting
focality and tumour margins in correlation with histology.
Until now, only a few investigations have focused on the
diagnostic value of dark-field imaging of dissected breast
samples [12, 13, 15–17, 22]. Stampanoni et al. analysed five
mastectomy samples using phase-contrast mammography and
found that the fused images created from the grating-based
absorption-, phase- and dark-field signals enable a better vi-
sualization of small tumours, skin infiltration and differentia-
tion between scars, healthy tissue and invasive cancer [16]. A
blinded, follow-up reader study came to the conclusion that
the fused images outperform conventional digital mammo-
grams in terms of overall image quality and sharpness [17].
Our results confirm these findings, indicating an improved
visibility of high frequency features (tissue strands, tumour
margins and spiculations) within the phase-contrast and
dark-field mammograms. Moreover, we could demonstrate
that sub-resolution dark-field sensitivity helps to detect highly
dispersed microcalcifications when examining complete
breast samples that are not visible in other modalities because
of size and volume, but that are nonetheless indicative of
malignancy. This is in accordance with studies by Anton
and Michel et al. who analysed slices of cancer-bearing
breast samples [12, 13]: they showed that the presence of
Fig. 4 Comparison of low- and high-dose dark-field mammography.
Low-dose (22 mGy mean glandular dose) dark-field mammography of
patient 1 conducted in one scan direction and 3 s exposure time per phase
step (a) and corresponding high-dose measurements (66 mGy mean
glandular dose per scan direction) conducted in two scan directions and
9 s exposure time per phase step (b) at 40 kVp/70 mA, respectively. Both
images offer equal quality in the detection of the tumour nodules
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microcalcifications within the tumour results in a high
dark-field signal, although the microcalcifications were
not detectable in the conventional mammogram.
Exceeding previously published studies on phase-contrast
mammography on whole mastectomy samples, our study ex-
emplarily indicates that dark-fieldmammographymay outper-
form all conventional imaging modalities in the detection of
small or low dense tumour nodules, fine structures and delin-
eation of tumour tissue. The correct determination of tumour
size and margins including tumour branches especially within
dense breast tissue may prevent incomplete resection and the
need for follow-up resections. Moreover, the capability of
detecting minor or highly dispersed calcium grains strongly
facilitates the sensitivity towards incipient calcification-
processes and therewith detection of early stage tumours. To
what extent the higher sensitivity in the detection of calcifica-
tions unresolved in conventional mammography will influ-
ence the percentage of overdiagnosis and lead to additional
breast biopsies remains debatable.
One challenge in breast cancer treatment is the prevention
of recurrent disease that can be caused by incomplete resection
or unnoticed multifocality and multicentricity at the time of
diagnosis. A considerable percentage (13–75 %) of primary
breast cancers occur as multifocal disease with often small
satellite nodules not detected in conventional breast imaging
[23]. Breast MRI has been shown to be more sensitive in the
detection of multifocality, but is time and cost intensive [23].
Our results indicate that dark-field mammography has the
potential to detect small tumours, especially if microcalcified,
at a better resolution than MRI, even though additional
lesions—depending on their localization—might still need
further histological assessment.
While the experimental measurements were conducted
within a clinically feasible frame (compact setup, conventional
X-ray tube and adequate sample compression) the applied ra-
diation dose exceeds the corresponding clinical ex vivo value
(average glandular dose ranging from 0.56 to 1.22 mGy) by
far. The estimated glandular dose applied at our experimental
setup was 66–70 mGy (total exposure time of 81 s) per pro-
jection and scan direction, depending on the sample thickness.
Since measurements were not conducted dose-optimized, sev-
eral aspects can be addressed to reduce the dose applied: an
increase of currently 13.2–49.4 % setup fringe visibility by
improving the beam quality (design energy, beam filtration)
and grating quality (duty cycle, grating substrate thickness,
grating height) would imply an approximately 14-fold de-
crease in dose for phase-contrast imaging. An optimization of
the detector with respect to the design energy of 27 keVand the
replacement of the X-ray target molybdenum with tungsten
could further double the setup efficiency.
A decrease of 9 to 3 s exposure time per step would further
decrease the dose by a factor of 3. Corresponding low-dose
measurements were exemplarily conducted in case of patient
1 (one scan direction), providing equivalent quality of detec-
tion for the microcalcified tumour nodules (Fig. 4) and suggest
that a much lower exposure time is practicable. These consid-
erations would imply a reduction of dose down to 0.8 mGy
(1.6 mGy in the case of bidirectional imaging) which lies
within the dose limits of 2.5 mGy set by the European guide-
lines for mammography [24].
Currently phase-contrast imaging suffers from limited clin-
ical experience and needs further technical improvements and
dose optimization (the first dose-compatible measurements at
2.2 mGy have been conducted with a revised setup recently).
Previous studies demonstrate few selected cancer cases and,
up to now, no independent multi-reader studies with larger
patient cohorts and lower prevalence of malignancy have been
performed. Thus, future studies will have to focus on the spe-
cific value of grating-based phase-contrast imaging for differ-
ent tumour entities and on larger patient cohorts to identify
those patients that will benefit the most from this promising
additional imaging modality.
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